BDX vs WST
Becton Dickinson and West Pharmaceutical Services, both Healthcare
Becton Dickinson is the larger company at $40B against $23B. On trailing earnings WST is the cheaper of the two at a P/E of 46.9 against 55.3, a gap that is only a bargain if the two are growing at similar rates. Over the past year WST returned +44% against +26% for BDX.
| Figure | BDX | WST |
|---|---|---|
| Last close | $184 | $366 |
| Market cap | $40B | $23B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 55.3 | 46.9 |
| Dividend yield | 2.3% | 0.2% |
| 1-year return | +26% | +44% |
| 5-year return | +0.7% | -16% |
| RyuScoresector-relative, 1–10 | 62/100 | 62/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Becton Dickinson
Revenue of $5.0B in Q3 2026, net income $377M. Its largest reported line is Connected Care, 38% of the disclosed total.
West Pharmaceutical Services
Revenue of $872M in Q2 2026, net income $154M. Its largest reported line is Proprietary Products, 83% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.